Transcode Therapeutics Inc (RNAZ) Stock Price, Quote & News

Company Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and t...

Industry: Biotechnology

Sector: Healthcare

Phone: 857-837-3099

Website: www.transcodetherapeutics.com

Address:

6 Liberty Square, Suite 2382, Boston, United States

BillionerOfKing Dec. 25 at 2:27 AM

$RNAZ Current Stock Price: $7.43

0 · Reply

BedrockBeta Dec. 24 at 11:44 AM

$RNAZ Forward visibility remains uneven as internal discipline offsets macro and competitive headwinds. Sustained traction would support a meaningful re-rating.

0 · Reply

zeph1985 Dec. 24 at 12:30 AM

$RNAZ LVRO cehck taht out,,

0 · Reply

Hovius Dec. 23 at 1:40 PM

$RNAZ “Dr. Philippe Calais stated that "I am very honored to deepen my commitment and lead TransCode's transformation into a one-of-a-kind leading oncology company at this critical time. We are grateful for CK Life Sciences' investment and their support of our miRNA candidate, TTX-MC138, as we now have the funding in place to fully execute our upcoming TTX-MC138 Phase 2.” New management, same lying attitude.

0 · Reply

Love_To_Learn Dec. 22 at 9:18 PM

$RNAZ PIVOTING

0 · Reply

phantomtrader75 Dec. 22 at 8:25 PM

$RNAZ POS

0 · Reply

Scoty_D Dec. 22 at 2:39 PM

$RNAZ Expandibg leadership, this should bring some vision, direction, and some inspiration. Alright leadedship, show us the way!

1 · Reply

DanaHiggenbotham181 Dec. 22 at 1:21 PM

TransCode Therapeutics (NASDAQ: $RNAZ) appoints Jack E. Stover to its Board of Directors. 🧬 Veteran life sciences executive with 30+ years experience. Joins Audit & Nominating Committees as company advances RNA & immuno-oncology pipeline.

0 · Reply

CodeSurge Dec. 21 at 9:13 PM

$RNAZ

0 · Reply

Khaled43 Dec. 19 at 8:33 PM

$JAGX $ONCO $OPEX $RNAZ Onco news very close 10+ soon Mark it

1 · Reply

TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

Dec 11, 2025, 8:05 AM EST - 14 days ago

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

Nov 17, 2025, 8:01 AM EST - 5 weeks ago

TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

Oct 14, 2025, 8:06 AM EDT - 2 months ago

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

May 28, 2025, 8:00 AM EDT - 7 months ago

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

May 8, 2025, 8:05 AM EDT - 8 months ago

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

May 5, 2025, 5:07 PM EDT - 8 months ago

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 2, 2025, 4:10 PM EDT - 8 months ago

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 1, 2025, 9:01 AM EDT - 8 months ago

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

Apr 21, 2025, 4:37 PM EDT - 8 months ago

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

Mar 27, 2025, 4:37 PM EDT - 9 months ago

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Mar 25, 2025, 6:24 PM EDT - 9 months ago

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

Mar 23, 2025, 11:11 PM EDT - 9 months ago

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 13, 2025, 7:47 AM EDT - 10 months ago

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Feb 25, 2025, 4:15 PM EST - 10 months ago

TransCode Therapeutics, Inc. Announces Results of Special Meeting

Feb 6, 2025, 8:00 AM EST - 11 months ago

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

Jan 14, 2025, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Jan 7, 2025, 8:00 AM EST - 1 year ago

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Dec 18, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Nov 29, 2024, 4:25 PM EST - 1 year ago

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

Nov 27, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

Nov 5, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Sep 17, 2024, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Sep 5, 2024, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

Jul 24, 2024, 4:05 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Closing of Public Offering

Jul 22, 2024, 10:30 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Jul 22, 2024, 4:07 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

May 29, 2024, 9:15 AM EDT - 1 year ago

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

May 13, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Open Letter to Shareholders

Apr 15, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

Apr 3, 2024, 9:10 AM EDT - 1 year ago

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Mar 28, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Mar 11, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

Mar 6, 2024, 4:15 PM EST - 1 year ago

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Feb 20, 2024, 8:00 AM EST - 2 years ago

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Jan 31, 2024, 4:05 PM EST - 2 years ago

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

Jan 29, 2024, 8:30 AM EST - 2 years ago

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Jan 22, 2024, 4:45 PM EST - 2 years ago

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

Jan 18, 2024, 1:27 PM EST - 2 years ago

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

Jan 12, 2024, 4:05 PM EST - 2 years ago

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

Jan 11, 2024, 8:00 AM EST - 2 years ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 4, 2024, 8:05 AM EST - 2 years ago

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

Dec 12, 2023, 8:30 AM EST - 2 years ago

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

Dec 5, 2023, 9:00 AM EST - 2 years ago

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

Dec 4, 2023, 4:10 PM EST - 2 years ago

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Nov 30, 2023, 2:53 PM EST - 2 years ago

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Nov 14, 2023, 4:30 PM EST - 2 years ago

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

Oct 30, 2023, 4:33 PM EDT - 2 years ago

TransCode Therapeutics Withdraws Public Offering

Oct 27, 2023, 8:00 AM EDT - 2 years ago

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

Oct 26, 2023, 4:19 PM EDT - 2 years ago

TransCode Therapeutics Announces Public Offering of Common Stock

BillionerOfKing Dec. 25 at 2:27 AM

$RNAZ Current Stock Price: $7.43

0 · Reply

BedrockBeta Dec. 24 at 11:44 AM

$RNAZ Forward visibility remains uneven as internal discipline offsets macro and competitive headwinds. Sustained traction would support a meaningful re-rating.

0 · Reply

zeph1985 Dec. 24 at 12:30 AM

$RNAZ LVRO cehck taht out,,

0 · Reply

Hovius Dec. 23 at 1:40 PM

0 · Reply

Love_To_Learn Dec. 22 at 9:18 PM

$RNAZ PIVOTING

0 · Reply

phantomtrader75 Dec. 22 at 8:25 PM

$RNAZ POS

0 · Reply

Scoty_D Dec. 22 at 2:39 PM

$RNAZ Expandibg leadership, this should bring some vision, direction, and some inspiration. Alright leadedship, show us the way!

1 · Reply

DanaHiggenbotham181 Dec. 22 at 1:21 PM

0 · Reply

CodeSurge Dec. 21 at 9:13 PM

$RNAZ

0 · Reply

Khaled43 Dec. 19 at 8:33 PM

$JAGX $ONCO $OPEX $RNAZ Onco news very close 10+ soon Mark it

1 · Reply

Hovius Dec. 19 at 12:08 PM

$RNAZ looks like they lied about not diluting.. Trash company… trash lying company.

0 · Reply

Hovius Dec. 18 at 10:31 PM

$RNAZ Only company that consistently gets punished on good news… 😝

0 · Reply

ShadowSnake Dec. 18 at 9:10 PM

$RNAZ WTF happened

1 · Reply

phantomtrader75 Dec. 18 at 8:09 PM

$RNAZ now it’s $7.21 on zero volume.

1 · Reply

phantomtrader75 Dec. 18 at 7:58 PM

$RNAZ WTF

0 · Reply

Dynk1973 Dec. 18 at 3:29 PM

$RNAZ What did I miss here, my account has a numbered company and no dollar value attached?

1 · Reply

Hovius Dec. 15 at 9:18 PM

$RNAZ lol.. that’s all the gains then…

0 · Reply

TheSniperGuy Dec. 15 at 4:40 PM

$RNAZ Fake start on Thursday, give it a few days!

0 · Reply

TheSniperGuy Dec. 13 at 4:04 PM

$RNAZ This is just a renewed permission, they are rolling the old one that they almost didn't use, to keep having the ability to sell whenever they please, (if)

0 · Reply

JohnTrack Dec. 12 at 11:16 PM

$RNAZ eyes on liquidity pockets!

0 · Reply

Zeusgodmd Dec. 12 at 11:11 PM

$RNAZ there are only 23 stockholders in September. They bought a melanoma treatment already fast tracked and are going to do a study with our drug in it. I don’t think it will make a difference we will get bought up by a big dog at some point. My bet Pfizer or Merck. They have the right war chest.

0 · Reply

JohnTrack Dec. 12 at 9:36 PM

$RNAZ new drop for the ticker!! https://www.rapidticker.com/news/rnaz-sec-filing-2ad335

0 · Reply

Market Cap	6.91M
Revenue (ttm)	0.00
Net Income (ttm)	-16.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,500
Avg Vol	19,704
Day's Range	N/A - N/A
Shares Out	917,000.00
Stochastic %K	10%
Beta	1.52
Analysts	Strong Buy
Price Target	$10.00